Evaluating telehealth lifestyle therapy versus telehealth psychotherapy for reducing depression in adults with COVID-19 related distress: the curbing anxiety and depression using lifestyle medicine (CALM) randomised non-inferiority trial protocol.
Depression
Diet
Exercise
Mental disorders
Mental health
Nutrition
Physical activity
Psychiatry
Psychotherapy
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
27 03 2022
27 03 2022
Historique:
received:
23
02
2022
accepted:
09
03
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
2
4
2022
Statut:
epublish
Résumé
There is increasing recognition of the substantial burden of mental health disorders at an individual and population level, including consequent demand on mental health services. Lifestyle-based mental healthcare offers an additional approach to existing services with potential to help alleviate system burden. Despite the latest Royal Australian New Zealand College of Psychiatrists guidelines recommending that lifestyle is a 'first-line', 'non-negotiable' treatment for mood disorders, few such programs exist within clinical practice. Additionally, there are limited data to determine whether lifestyle approaches are equivalent to established treatments. Using an individually randomised group treatment design, we aim to address this gap by evaluating an integrated lifestyle program (CALM) compared to an established therapy (psychotherapy), both delivered via telehealth. It is hypothesised that the CALM program will not be inferior to psychotherapy with respect to depressive symptoms at 8 weeks. The study is being conducted in partnership with Barwon Health's Mental Health, Drugs & Alcohol Service (Geelong, Victoria), from which 184 participants from its service and surrounding regions are being recruited. Eligible participants with elevated psychological distress are being randomised to CALM or psychotherapy. Each takes a trans-diagnostic approach, and comprises four weekly (weeks 1-4) and two fortnightly (weeks 6 and 8) 90-min, group-based sessions delivered via Zoom (digital video conferencing platform). CALM focuses on enhancing knowledge, behavioural skills and support for improving dietary and physical activity behaviours, delivered by an Accredited Exercise Physiologist and Accredited Practising Dietitian. Psychotherapy uses cognitive behavioural therapy (CBT) delivered by a Psychologist or Clinical Psychologist, and Provisional Psychologist. Data collection occurs at baseline and 8 weeks. The primary outcome is depressive symptoms (assessed via the Patient Health Questionnaire-9) at 8 weeks. Societal and healthcare costs will be estimated to determine the cost-effectiveness of the CALM program. A process evaluation will determine its reach, adoption, implementation and maintenance. If the CALM program is non-inferior to psychotherapy, this study will provide the first evidence to support lifestyle-based mental healthcare as an additional care model to support individuals experiencing psychological distress. Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12621000387820 , Registered 8 April 2021.
Sections du résumé
BACKGROUND
There is increasing recognition of the substantial burden of mental health disorders at an individual and population level, including consequent demand on mental health services. Lifestyle-based mental healthcare offers an additional approach to existing services with potential to help alleviate system burden. Despite the latest Royal Australian New Zealand College of Psychiatrists guidelines recommending that lifestyle is a 'first-line', 'non-negotiable' treatment for mood disorders, few such programs exist within clinical practice. Additionally, there are limited data to determine whether lifestyle approaches are equivalent to established treatments. Using an individually randomised group treatment design, we aim to address this gap by evaluating an integrated lifestyle program (CALM) compared to an established therapy (psychotherapy), both delivered via telehealth. It is hypothesised that the CALM program will not be inferior to psychotherapy with respect to depressive symptoms at 8 weeks.
METHODS
The study is being conducted in partnership with Barwon Health's Mental Health, Drugs & Alcohol Service (Geelong, Victoria), from which 184 participants from its service and surrounding regions are being recruited. Eligible participants with elevated psychological distress are being randomised to CALM or psychotherapy. Each takes a trans-diagnostic approach, and comprises four weekly (weeks 1-4) and two fortnightly (weeks 6 and 8) 90-min, group-based sessions delivered via Zoom (digital video conferencing platform). CALM focuses on enhancing knowledge, behavioural skills and support for improving dietary and physical activity behaviours, delivered by an Accredited Exercise Physiologist and Accredited Practising Dietitian. Psychotherapy uses cognitive behavioural therapy (CBT) delivered by a Psychologist or Clinical Psychologist, and Provisional Psychologist. Data collection occurs at baseline and 8 weeks. The primary outcome is depressive symptoms (assessed via the Patient Health Questionnaire-9) at 8 weeks. Societal and healthcare costs will be estimated to determine the cost-effectiveness of the CALM program. A process evaluation will determine its reach, adoption, implementation and maintenance.
DISCUSSION
If the CALM program is non-inferior to psychotherapy, this study will provide the first evidence to support lifestyle-based mental healthcare as an additional care model to support individuals experiencing psychological distress.
TRIAL REGISTRATION
Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12621000387820 , Registered 8 April 2021.
Identifiants
pubmed: 35346115
doi: 10.1186/s12888-022-03840-3
pii: 10.1186/s12888-022-03840-3
pmc: PMC8958477
doi:
Types de publication
Equivalence Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
219Informations de copyright
© 2022. The Author(s).
Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Aust N Z J Psychiatry. 2015 Dec;49(12):1087-206
pubmed: 26643054
Clin Psychol Rev. 2018 Feb;59:52-60
pubmed: 29126747
PLoS One. 2013 Sep 18;8(9):e75156
pubmed: 24058660
BMC Med. 2010 Mar 24;8:18
pubmed: 20334633
Diabetes Care. 2014 Apr;37(4):934-42
pubmed: 24319121
Am J Public Health. 2015 May;105(5):e38-42
pubmed: 25790393
J Affect Disord. 2015 Mar 15;174:400-10
pubmed: 25553400
Aliment Pharmacol Ther. 2016 Oct;44(7):693-703
pubmed: 27492648
Br J Sports Med. 2020 Dec;54(24):1451-1462
pubmed: 33239350
Sleep Med. 2001 Jul;2(4):297-307
pubmed: 11438246
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
BMC Fam Pract. 2021 Jul 1;22(1):143
pubmed: 34210284
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Curr Psychiatry Rep. 2019 Feb 7;21(2):10
pubmed: 30729322
Diabetes Care. 2009 Aug;32(8):1418-20
pubmed: 19401442
Depress Anxiety. 2016 Sep;33(9):783-91
pubmed: 27322710
BMC Med. 2017 Jan 30;15(1):23
pubmed: 28137247
Nutr Neurosci. 2018 Sep;21(7):487-501
pubmed: 28424045
Psychosom Med. 2019 Apr;81(3):265-280
pubmed: 30720698
PLoS One. 2010 Jun 08;5(6):e10939
pubmed: 20544030
Sci Rep. 2020 Oct 16;10(1):17548
pubmed: 33067493
Psychol Med. 2019 Jun;49(8):1266-1274
pubmed: 30688184
Aust N Z J Public Health. 2001 Dec;25(6):494-7
pubmed: 11824981
J Affect Disord. 2021 Oct 1;293:406-414
pubmed: 34246949
BMC Psychiatry. 2010 Mar 21;10:25
pubmed: 20302678
J Affect Disord. 2014 Aug;164:155-64
pubmed: 24856569
Heart Lung Circ. 2020 Jul;29(7):960-963
pubmed: 32561126
J Psychiatr Res. 2016 Jun;77:42-51
pubmed: 26978184
BMC Psychiatry. 2020 Mar 6;20(1):108
pubmed: 32143714
J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86
pubmed: 11132119
Int J Epidemiol. 2012 Apr;41(2):377-85
pubmed: 21172932
BMC Public Health. 2007 Sep 19;7:249
pubmed: 17877832
Diabetologia. 2013 Feb;56(2):284-93
pubmed: 23093136
Transl Psychiatry. 2021 Sep 16;11(1):478
pubmed: 34531367
Heart. 2016 Jul 1;102(13):1009-16
pubmed: 27091846
Ment Health Phys Act. 2020 Oct;19:100345
pubmed: 32834833
Sports Med. 2020 Jan;50(1):151-170
pubmed: 31541410
Patient. 2014;7(1):85-96
pubmed: 24271592
Nutr Neurosci. 2020 Oct;23(10):770-778
pubmed: 30570386
BMC Public Health. 2018 May 22;18(1):599
pubmed: 29783983
Am J Phys Med Rehabil. 2019 Oct;98(10):850-858
pubmed: 31021823
Am J Psychiatry. 2017 Jun 1;174(6):546-556
pubmed: 28335624
JAMA Psychiatry. 2019 Jul 1;76(7):700-707
pubmed: 30994877
Lancet. 2021 Nov 6;398(10312):1700-1712
pubmed: 34634250
Death Stud. 2020;44(7):393-401
pubmed: 32299304
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
Ann Pharmacother. 2011 May;45(5):569-75
pubmed: 21521862
Neuroimage. 2018 Feb 1;166:230-238
pubmed: 29113943
Med J Aust. 2010 Jun 7;192(S11):S4-11
pubmed: 20528707
Fam Pract. 2019 Jan 25;36(1):53-63
pubmed: 30188992
Ann Behav Med. 2014 Oct;48(2):163-74
pubmed: 24570217
Am J Psychiatry. 2010 Mar;167(3):305-11
pubmed: 20048020
Lancet Psychiatry. 2016 Jan;3(1):e1
pubmed: 26772067
Depress Anxiety. 2018 Jun;35(6):502-514
pubmed: 29451967
Prev Med. 2021 Dec;153:106851
pubmed: 34662595
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
World Psychiatry. 2020 Oct;19(3):360-380
pubmed: 32931092
J Clin Epidemiol. 2016 Mar;71:35-42
pubmed: 26464194